FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

FibroBiologics (Nasdaq: FBLG) will present preclinical data for its CYPS317 psoriasis program at the Society for Investigative Dermatology Annual Meeting, May 13–15, 2026, in Chicago.

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) will present preclinical data for its CYPS317 psoriasis program at the Society for Investigative Dermatology Annual Meeting, May 13–15, 2026, in Chicago. The poster session featuring Chuo Fang, MD, Ph.D., is scheduled for May 15, 2026, 4:30–6:00 p.m. CT in Salons B, C, D; Williford – 3rd Floor.

For more information, attendees can visit FibroBiologics' website, email info@fibrobiologics.com, or follow the company on LinkedIn, YouTube, Facebook, or X.

Argus Apr 30 session

+0.76% close to close Open Argus

Details

News Market Reaction – FBLG

On Apr 30, the day this news came out, FBLG closed 0.76% above the previous close.

Data tracked by StockTitan Argus for the Apr 30 session.

Key Figures

Patent portfolio: 270+ patents Meeting dates: May 13–15, 2026 Session time: 4:30–6:00 p.m. CT

Patent portfolio

270+ patents

Issued and pending IP cited in company description

Meeting dates

May 13–15, 2026

Society for Investigative Dermatology Annual Meeting

Session time

4:30–6:00 p.m. CT

CYPS317 psoriasis poster session on May 15, 2026

Historical Context

5 past events · Latest: Apr 20

5 events

1. Apr 20

   Nasdaq compliance update

   24h Move

   -0.7%

   Nasdaq confirmed FBLG met equity and $1.00 bid listing requirements.

2. Apr 10

   Preclinical data presentation

   24h Move

   -2.2%

   Preclinical thymus organoid platform data presented at aging and immunity meeting.

3. Apr 02

   Public offering closing

   24h Move

   -0.7%

   Closed $3M best-efforts offering with shares and warrants at $1.32.

4. Mar 31

   Public offering pricing

   24h Move

   +0.8%

   Priced $3M offering of common stock and warrants at $1.32.

5. Mar 31

   Clinical manufacturing

   24h Move

   +0.8%

   Completed first CYWC628 batch under CGMP for planned Phase 1/2 trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

preclinical, psoriasis, fibroblasts

3 terms

preclinical medical

"announced the presentation of preclinical data from its CYPS317 program"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

psoriasis medical

"CYPS317 program for psoriasis at the Society for Investigative Dermatology"

Psoriasis is a chronic skin condition where the body's defenses cause skin cells to build up rapidly, producing red, scaly, and often itchy patches. It matters to investors because it creates a steady market for long-term treatments, devices and services—similar to a recurring customer need—affecting drug development, clinical trial pipelines, pricing, and healthcare spending across pharmaceuticals and medical providers.

fibroblasts medical

"potential cures for chronic diseases using fibroblasts and fibroblast-derived materials"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the presentation of preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting taking place May 13-15, 2026, in Chicago, Illinois.

Details of the presentations are as follows:
Event: Society for Investigative Dermatology 2026 Annual Meeting
Presenter: Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiologics
Session Date and Time: 4:30 p.m. – 6 p.m. CT on May 15, 2026
Location: Salons B, C, D; Williford – 3^rd Floor

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is FibroBiologics (FBLG) presenting CYPS317 preclinical data at SID 2026?

The presentation is scheduled for May 15, 2026, 4:30–6:00 p.m. CT. According to FibroBiologics, the session will take place in Salons B, C, D; Williford – 3rd Floor at the Society for Investigative Dermatology Annual Meeting in Chicago.

What will FibroBiologics present about CYPS317 (FBLG) at the SID 2026 meeting?

FibroBiologics will present preclinical data from its CYPS317 psoriasis program. According to FibroBiologics, the poster outlines experimental findings and program details intended for the dermatology research audience at SID 2026.

Who is presenting FibroBiologics' (FBLG) poster on CYPS317 at SID 2026?

The poster will be presented by Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiologics. According to FibroBiologics, Dr. Fang will present the CYPS317 preclinical data during the May 15 session in Chicago.

Where can investors and researchers find more information about FibroBiologics' (FBLG) SID 2026 presentation?

More information is available on the company's website and via info@fibrobiologics.com. According to FibroBiologics, attendees can also follow LinkedIn, YouTube, Facebook, or X for updates and related materials.

Does the SID 2026 poster on CYPS317 indicate clinical trial timing for FibroBiologics (FBLG)?

The announcement reports preclinical data only and does not state clinical trial start dates. According to FibroBiologics, the presentation focuses on preclinical findings for the CYPS317 psoriasis program without clinical-timing details.